This website is for UK Healthcare Professionals only

Resources

For healthcare professionals

BOTOX® Dosage and Administration Guide

This guide provides information on the recommended dosage and administration of BOTOX® for overactive bladder (OAB) and neurogenic detrusor overactivity (NDO). The recommended injection sites and additional information specific to each indication is also included, along with important safety information.

To receive a copy of this guide, please submit your details on the Contact Us page and tick BOTOX® Dosage and Administration Guide.

 

BOTOX® Service Development Guide

This service guide has been developed to support healthcare professionals who would like support with establishing or increasing the capacity of a BOTOX® injection service, for the treatment of patients with overactive bladder and/or neurogenic detrusor overactivity. This guide includes key steps for establishing or expanding a nurse-led outpatient service, as well as Getting it Right First Time (GIRFT) case studies showing examples of nurse-led outpatient BOTOX® services, hints and useful tips and operational and funding considerations.

To receive a copy of this guide, please submit your details on the Contact Us page and tick BOTOX® Service Development Guide.

BOTOX® Procedure Video for Overactive Bladder

This video provides information on how to administer BOTOX® injections for OAB. Marcus Drake, Professor of Physiological Urology at the Bristol Urological Institute at Bristol University, talks through patient selection, how to prepare and administer BOTOX® injections and how to follow up with patients.

BOTOX® Nurse-led Service Video

In this video, Julia Taylor, Consultant Nurse in Urology at Salford Royal NHS Foundation Trust, discusses the development and benefits of a nurse-led BOTOX® urology service.

Steve Foley talking head: How to consent a patient for BOTOX® (botulinum toxin type A) treatment

This video has been developed to support healthcare professionals in their understanding of the information that should be provided to a patient who may require BOTOX® treatment for OAB.

Stephen Foley, Consultant Urological Surgeon at the Royal Berkshire Hospital in Reading, discusses how he consents a patient for treatment as well as the key information he communicates to patients about BOTOX® treatment for OAB.

To view this talking head, please submit your details on the Contact Us page and tick Steve Foley talking head: How to consent a patient for BOTOX® (botulinum toxin type A) treatment.

Steve Foley talking head: Discussing the need to self-catheterise following BOTOX® (botulinum toxin type A) treatment

This video has been developed to support healthcare professionals in their understanding of which patients may be required to learn self-catheterisation following BOTOX® treatment for OAB.

Stephen Foley, Consultant Urological Surgeon at the Royal Berkshire Hospital in Reading, discusses his clinical approach to the topic of self-catheterisation and how to explain potential need of self-catheterisation to patients in some cases.

To view this talking head, please submit your details on the Contact Us page and tick Steve Foley talking head: Discussing the need to self-catheterise following BOTOX® (botulinum toxin type A) treatment.

EMBARK Study Clinical Summary

This clinical summary provides information on the EMBARK Phase III clinical study for BOTOX® in patients with OAB. It contains an overview of the study design, the key primary and secondary endpoints, along with an overview of the results and conclusions

If you are interested in discussing this clinical summary further, please submit your details on the Contact Us page. Tick EMBARK Study Clinical Summary and a member of the AbbVie team will be in contact with you.

DIGNITY Study Clinical Summary

This clinical summary provides information on the DIGNITY Phase III clinical studies for BOTOX® in patients with NDO. It contains an overview of the study design, the key primary and secondary endpoints, along with overview of the results and conclusions.

If you are interested in discussing this clinical summary further, please submit your details on the Contact Us page. Tick DIGNITY Study Clinical Summary and a member of the AbbVie team will be in contact with you.

BOTOX® Toolkit to Encourage And Motivate (TEAM)

This resource is designed to help, motivate and engage your team during face-to-face or virtual meetings.

Part 1 includes ice-breaker activities, mood barometers and motivational quotes that can be downloaded and incorporated into your meeting slides.

Part 2 offers further valuable tools to support your face-to-face or virtual meetings. Useful hints and tips on how to get the most out of your virtual meeting platform are also available in this toolkit.


Educational resources for healthcare professionals

BOTOX® (botulinum toxin type A) for the management of bladder dysfunctions

These educational modules have been developed to support healthcare professionals who manage patients with OAB and NDO.

These modules are designed to be used at peer-to-peer meetings, presented either by a healthcare professional or by an AbbVie Key Account Manager. If you are interested in discussing these modules further, please submit your details on the Contact us page. Tick the appropriate box which relates to the module(s) you are interested in and a member of the Abbvie team will be in contact with you.

Prevalence, Diagnosis and Patient Selection

  • Review of the definition and prevalence of OAB
  • The definition and aetiology of NDO
  • The impact of OAB on patients’ quality of life and how this impact is measured
  • The economic impact of OAB

The Science of Overactive Bladder and Neurogenic Detrusor Overactivity

  • Review of normal reflex and central control of the bladder
  • Review of neurotransmitters and neuropeptides involved in bladder control
  • The motor and sensory pathways associated with OAB symptoms
  • The proposed pathophysiological mechanisms underlying OAB and NDO

Management Guidelines for Overactive Bladder and Neurogenic Detrusor Overactivity

  • An overview of the assessment and diagnosis of OAB and various guideline recommendations
  • An overview of the assessment and diagnosis of NDO and urodynamic guidelines
  • Review the current OAB treatment guidelines including use of BOTOX®, anticholinergics and surgical procedures
  • Review the current NDO treatment guidelines including use of BOTOX®, anticholinergics and surgical procedures

What is BOTOX® (Botulinum Toxin Type A)?

  • An overview of what BOTOX® is and how BOTOX® works
  • A brief history of BOTOX®
  • How BOTOX® is a focal therapy for multiple therapeutic indications
  • Why botulinum toxin type A units are not interchangeable
  • An overview of the use of BOTOX® in urology 

BOTOX® (Botulinum Toxin Type A) Efficacy and Tolerability Data in Overactive Bladder and Neurogenic Detrusor Overactivity

  • An overview of the OAB BOTOX® clinical development programme
  • Review the results from the Phase III EMBARK studies of BOTOX® for OAB
  • Review the results of the DIGNITY study programme of BOTOX® for NDO
  • The efficacy and safety of BOTOX® for OAB and NDO
  • The impact on quality of life for patients with OAB or NDO who receive BOTOX®

Patient Selection and Administration of BOTOX®

  • Criteria for appropriate patient selection
  • Examples of best-practice patient-doctor communication
  • Pre-injection, injection and post-injection recommendations for the use of BOTOX® for the treatment of OAB and NDO
  • Reconstitution protocols, needle and cystoscope selection
  • Injection technique protocols and post-injection precautions, including patient monitoring and re-injection protocols

Resources for your patients

A patient guide for BOTOX® (botulinum toxin type A): overactive bladder

To support your patients with OAB that have been prescribed BOTOX®, this guide provides information on how BOTOX® works, what patients can expect before and after treatment and any potential side-effects of BOTOX® treatment.

The information in this guide does not replace the Patient Information Leaflet that is included with the prescribed medication.

To receive a copy of this guide, please submit your details on the Contact Us page and tick A patient guide for BOTOX® (botulinum toxin type A): overactive bladder.

A patient guide for BOTOX® (botulinum toxin type A): neurogenic detrusor overactivity 

To support your patients with NDO that have been prescribed BOTOX®, this guide provides information on how BOTOX® works, what patients can expect before and after treatment and any potential side-effects of BOTOX® treatment.

The information in this guide does not replace the Patient Information Leaflet that is included with the prescribed medication.

To receive a copy of this guide, please submit your details on the Contact Us page and tick A patient guide for BOTOX® (botulinum toxin type A): neurogenic detrusor overactivity.

NDO: neurogenic detrusor overactivity; OAB: overactive bladder.

BOTOX® is indicated for the management of bladder dysfunctions in adult patients who are not adequately managed with anticholinergics: overactive bladder with symptoms of urinary incontinence, urgency and frequency; neurogenic detrusor overactivity with urinary incontinence due to subcervical spinal cord injury (traumatic or non-traumatic), or multiple sclerosis.5

 

References

  1. Allergan. Data on file. INT/0423/2016
  2. Aurora S K, Winner P et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 2011;51(9):1358-1373
  3. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of onabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain 2018;19(1):13
  4. Allergan Ltd. Data on file 014
  5. BOTOX® Summary of Product Characteristics. Available at: www.medicines.org.uk. Accessed December 2022

Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use.

 

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/

Adverse events should also be reported to AbbVie on [email protected] 

 

Date of preparation: December 2022. UK-BUO-220090.